Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Imitrex approval

This article was originally published in The Tan Sheet

Executive Summary

FDA grants Teva Pharmaceuticals tentative approval for a generic version of GlaxoSmithKline's migraine treatment Imitrex Nov. 29. Final approval of the 25 mg, 50 mg and 100 mg Sumatriptan Succinate Tablets is expected upon expiry of patent protection in February 2009, according to the Jerusalem-based company. In October, Dr. Reddy's announced it will launch an "authorized" generic version of the drug in Q4 2008 (1"The Tan Sheet" Oct. 16, 2006, In Brief)...

You may also be interested in...

Generic Imitrex

Dr. Reddy's will launch an "authorized" generic version of GlaxoSmithKline's migraine treatment Imitrex (sumatriptan) in the fourth quarter of 2008, according to a patent-infringement settlement agreement announced by the companies Oct. 10. Settlement of the patent litigation allows for earlier entry of a generic version of Imitrex; the suit related to GSK's patent no. 5,037,845, which has pediatric exclusivity extending through February 2009. The agreement also allows India-based Dr. Reddy's to exclusively distribute generic Imitrex in the 25, 50 and 100 mg strengths. GSK filed the patent infringement suit against Dr. Reddy's in December 2003 after the company submitted an ANDA seeking approval of sumatriptan. A 50-mg dose of sumatriptan (marketed by GSK as Imigran Recovery) was approved for nonprescription "Pharmacy" sale by the UK's Medicines & Healthcare products Regulatory Agency in May (1"The Tan Sheet" May 22, 2006, p. 3). GSK is also working with its partner Pozen toward a mid-2007 launch of a next-generation Rx migraine medicine Trexima, combining sumatriptan with naproxen...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts